期刊
LEUKEMIA
卷 35, 期 7, 页码 2017-2029出版社
SPRINGERNATURE
DOI: 10.1038/s41375-020-01077-1
关键词
-
资金
- Deutsche Forschungsgemeinschaft [BU 2508/4-1]
- Bundesministerium fur Bildung und Forschung (NGFNplus)
- Jose Carreras Stiftung [106682]
One important limitation of FLT3 tyrosine kinase inhibitors in FLT3-ITD positive AML is the development of resistance. Research has found that JAK1 V658F mutation leads to reactivation of the CSF2RB-STAT5 pathway, while JAK family activating mutations induce resistance to FLT3-ITD inhibition, which can be overcome by dual FLT3/JAK inhibition.
An important limitation of FLT3 tyrosine kinase inhibitors (TKIs) in FLT3-ITD positive AML is the development of resistance. To better understand resistance to FLT3 inhibition, we examined FLT3-ITD positive cell lines which had acquired resistance to midostaurin or sorafenib. In 6 out of 23 TKI resistant cell lines we were able to detect a JAK1 V658F mutation, a mutation that led to reactivation of the CSF2RB-STAT5 pathway. Knockdown of JAK1, or treatment with a JAK inhibitor, resensitized cells to FLT3 inhibition. Out of 136 patients with FLT3-ITD mutated AML and exposed to FLT3 inhibitor, we found seven different JAK family mutations in six of the cases (4.4%), including five bona fide, activating mutations. Except for one patient, the JAK mutations occurred de novo (n = 4) or displayed increasing variant allele frequency after exposure to FLT3 TKI (n = 1). In vitro each of the five activating variants were found to induce resistance to FLT3-ITD inhibition, which was then overcome by dual FLT3/JAK inhibition. In conclusion, our data characterize a novel mechanism of resistance to FLT3-ITD inhibition and may offer a potential therapy, using dual JAK and FLT3 inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据